Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18640824 | COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18402596 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | January 2024 | April 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18346437 | AFFINITY MOLECULES AND METHODS FOR THEIR USE | July 2023 | April 2024 | Allow | 9 | 0 | 1 | No | No |
| 18323438 | TrkA ANTIBODY AND APPLICATION THEREOF | May 2023 | April 2024 | Allow | 11 | 1 | 1 | No | No |
| 18313134 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | May 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18157643 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | February 2024 | Allow | 12 | 1 | 1 | No | No |
| 18017065 | IL23R BINDING MOLECULES AND METHODS OF USE | January 2023 | February 2024 | Allow | 12 | 1 | 1 | No | No |
| 18056110 | STEROID ACID-PEPTIDE BASED CYTOTOXIC COMPOUNDS | November 2022 | September 2023 | Allow | 10 | 1 | 1 | No | No |
| 17932653 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | September 2022 | October 2023 | Allow | 13 | 1 | 1 | No | No |
| 17929458 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | September 2022 | February 2024 | Allow | 17 | 1 | 0 | No | No |
| 17900161 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | August 2022 | July 2023 | Allow | 11 | 0 | 1 | No | No |
| 17881156 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN | August 2022 | January 2024 | Abandon | 17 | 2 | 0 | No | Yes |
| 17815535 | COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF | July 2022 | January 2023 | Allow | 5 | 1 | 0 | No | No |
| 17846900 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | June 2022 | April 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 17807801 | ANTI CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF HEPATIC DISEASES | June 2022 | April 2024 | Allow | 22 | 0 | 0 | No | No |
| 17836671 | NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS | June 2022 | November 2022 | Allow | 5 | 1 | 0 | No | No |
| 17824294 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | May 2022 | May 2024 | Allow | 24 | 0 | 0 | No | No |
| 17739596 | CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS | May 2022 | July 2022 | Allow | 2 | 0 | 0 | No | No |
| 17733479 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE | April 2022 | April 2023 | Allow | 11 | 2 | 1 | No | No |
| 17681573 | Bispecific antibodies binding ALK-1 and BMPR-2 | February 2022 | October 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17551147 | Bi-Specific Targeting Human NKG2DL and CLDN18A2 Chimeric Antigen Receptor Cells, Preparation Method and Application Thereof | December 2021 | April 2022 | Allow | 4 | 0 | 1 | No | No |
| 17457142 | Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereof | December 2021 | March 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17529927 | Anti-MARCO Antibodies and Uses Thereof | November 2021 | July 2022 | Allow | 8 | 0 | 1 | No | No |
| 17527956 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | November 2021 | May 2022 | Allow | 6 | 1 | 0 | No | No |
| 17517559 | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS | November 2021 | June 2022 | Allow | 8 | 1 | 1 | No | No |
| 17507492 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | October 2021 | May 2024 | Allow | 31 | 1 | 0 | No | No |
| 17451622 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | October 2021 | February 2024 | Allow | 28 | 1 | 0 | No | No |
| 17499272 | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods | October 2021 | June 2023 | Allow | 20 | 3 | 1 | Yes | No |
| 17484467 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | September 2021 | September 2023 | Allow | 24 | 1 | 0 | No | No |
| 17471744 | CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS | September 2021 | December 2021 | Allow | 4 | 0 | 0 | No | No |
| 17469797 | Stable Anti-OSMR Antibody Formulation | September 2021 | September 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17466395 | ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS | September 2021 | February 2024 | Allow | 29 | 1 | 1 | No | No |
| 17463065 | METHODS FOR REDUCTION OF PATHOLOGICAL FIBROSIS AND ASSOCIATED DISORDERS AND DISEASES | August 2021 | January 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17458612 | Specific Chimeric Antigen Receptor Cells Targeting Human CLDN18A2, Preparation Method and Application Thereof | August 2021 | March 2022 | Allow | 7 | 1 | 1 | Yes | No |
| 17410153 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | August 2021 | February 2024 | Allow | 30 | 1 | 1 | No | No |
| 17410129 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER | August 2021 | September 2023 | Allow | 25 | 1 | 0 | No | No |
| 17407758 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN | August 2021 | April 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17406400 | ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF | August 2021 | June 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17399527 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER | August 2021 | February 2024 | Allow | 30 | 2 | 0 | No | No |
| 17397510 | ANTI-MET ANTIBODIES AND USES THEREOF | August 2021 | October 2023 | Allow | 26 | 1 | 0 | No | No |
| 17395676 | HCMV ENTRY INHIBITORS | August 2021 | January 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17395331 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | August 2021 | February 2024 | Allow | 30 | 2 | 0 | No | No |
| 17392434 | COMPOSITIONS COMPRISING A P75 TUMOR NECROSIS FACTOR RECEPTOR/IG FUSION PROTEIN | August 2021 | November 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17388052 | COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA | July 2021 | February 2024 | Allow | 31 | 1 | 1 | No | No |
| 17382948 | ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS | July 2021 | July 2023 | Allow | 24 | 0 | 1 | No | No |
| 17355839 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE | June 2021 | July 2022 | Allow | 13 | 1 | 1 | No | No |
| 17353414 | Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens | June 2021 | October 2023 | Allow | 28 | 1 | 0 | No | No |
| 17350608 | ALK7 BINDING PROTEINS AND USES THEREOF | June 2021 | April 2023 | Allow | 22 | 0 | 0 | No | No |
| 17342949 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | June 2021 | November 2023 | Allow | 29 | 2 | 0 | No | No |
| 17342749 | Anti-Trkb Monoclonal Antibodies And Methods of Use | June 2021 | March 2024 | Allow | 33 | 1 | 1 | No | No |
| 17342514 | INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESIS | June 2021 | September 2023 | Allow | 27 | 1 | 1 | No | No |
| 17323917 | NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS | May 2021 | April 2022 | Allow | 11 | 3 | 0 | Yes | No |
| 17302514 | EXPRESSION OF NOVEL CELL TAGS | May 2021 | June 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17246005 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | April 2021 | March 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17245123 | ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF | April 2021 | July 2023 | Allow | 26 | 1 | 0 | No | No |
| 17243309 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN | April 2021 | August 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17238995 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | April 2021 | September 2023 | Allow | 29 | 1 | 1 | No | No |
| 17233359 | GPCR HETEROMER INHIBITORS AND USES THEREOF | April 2021 | November 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17231400 | USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17227017 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS | April 2021 | February 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17208409 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | March 2021 | November 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17205144 | DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF | March 2021 | October 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17204622 | USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE | March 2021 | March 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17196810 | NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS | March 2021 | May 2023 | Allow | 26 | 2 | 0 | No | No |
| 17178926 | TISSUE TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR | February 2021 | March 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17177614 | COMPOUNDS FOR USE IN THE TREATMENT OF TELOMERE RELATED DISEASES AND/OR TELOMERE RELATED MEDICAL CONDITIONS | February 2021 | October 2023 | Allow | 32 | 1 | 0 | No | No |
| 17176820 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | February 2021 | April 2021 | Allow | 2 | 0 | 0 | No | No |
| 17172490 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY | February 2021 | March 2023 | Allow | 25 | 1 | 0 | No | No |
| 17166177 | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP | February 2021 | July 2023 | Allow | 29 | 2 | 1 | No | No |
| 17157810 | ANTI-ROR1 ANTIBODIES AND USES THEREOF | January 2021 | November 2023 | Allow | 33 | 1 | 1 | No | No |
| 17150993 | IMMUNOMODULATORY FUSION PROTEINS | January 2021 | March 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17130928 | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS FOR USE OF SAME | December 2020 | August 2022 | Allow | 20 | 0 | 0 | No | No |
| 17128678 | SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS | December 2020 | March 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17117625 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17102112 | ASPGR ANTIBODIES AND USES THEREOF | November 2020 | October 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16951192 | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF | November 2020 | October 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 16950755 | SINGLE-CHAIN CD27-RECEPTOR AGONIST PROTEINS | November 2020 | February 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17055789 | ANTI-HUMAN INTERLEUKIN 17A MONOCLONAL ANTIBODY AND APPLICATION THEREOF | November 2020 | June 2024 | Allow | 43 | 0 | 1 | No | No |
| 17093474 | RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 1 (ROR1) SINGLE CHAIN FV ANTIBODY FRAGMENT CONJUGATES AND METHODS OF USE THEREOF | November 2020 | August 2022 | Allow | 21 | 0 | 0 | No | No |
| 17091552 | DOSING REGIMEN | November 2020 | July 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17052785 | MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF | November 2020 | May 2024 | Allow | 42 | 2 | 1 | No | No |
| 17052425 | IMMUNE EFFECTOR CELL AND USE THEREOF | November 2020 | May 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17049915 | PHARMACEUTICAL FORMULATIONS FOR NOVEL FELINE ERYTHROPOIETIN RECEPTOR AGONISTS | October 2020 | February 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17077502 | CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS | October 2020 | May 2021 | Allow | 7 | 1 | 1 | No | No |
| 17017238 | Compositions and Methods Comprising Prostate Stem Cell Antigen (PSCA) Chimeric Antigen Receptors (CARs) | September 2020 | May 2023 | Allow | 32 | 2 | 1 | No | No |
| 17010162 | ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY-DRUG CONJUGATE | September 2020 | March 2021 | Allow | 7 | 1 | 1 | No | No |
| 15733553 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | August 2020 | December 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16999374 | ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF | August 2020 | September 2023 | Allow | 37 | 2 | 1 | Yes | Yes |
| 16996265 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | August 2020 | March 2023 | Allow | 31 | 3 | 0 | No | No |
| 16991762 | ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | August 2020 | April 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16935582 | COMBINATION OF ANTI-FGFR4-ANTIBODY AND BILE ACID SEQUESTRANT | July 2020 | February 2023 | Allow | 31 | 3 | 1 | No | No |
| 16962817 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | July 2020 | March 2021 | Allow | 8 | 1 | 1 | No | No |
| 16928819 | ANTI-FLT-1 ANTIBODIES IN TREATING DUCHENNE MUSCULAR DYSTROPHY | July 2020 | October 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16922734 | THERAPEUTIC TARGETING OF TISSUE-RESIDENT MEMORY T CELLS | July 2020 | June 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16921695 | METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH | July 2020 | January 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16913963 | ANTI-GITR ANTIBODIES AND USES THEREOF | June 2020 | April 2022 | Allow | 21 | 0 | 0 | No | No |
| 16956889 | SCREENING METHOD FOR MATERIALS THAT SUPPRESS CHARACTERISTIC BODY ODOR OF ELDERLY PEOPLE | June 2020 | December 2022 | Allow | 30 | 1 | 0 | No | No |
| 16906669 | DETECTION OF ANALYTES USING LIVE CELLS | June 2020 | September 2023 | Allow | 39 | 3 | 0 | No | No |
| 16901160 | FGFR3 Binding Molecules | June 2020 | February 2022 | Allow | 20 | 0 | 0 | No | No |
| 16902212 | METHODS OF TREATING CORONAVIRUS INFECTION | June 2020 | February 2021 | Allow | 8 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, RUIXIANG.
With a 15.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LI, RUIXIANG works in Art Unit 1646 and has examined 1,235 patent applications in our dataset. With an allowance rate of 41.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner LI, RUIXIANG's allowance rate of 41.9% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LI, RUIXIANG receive 1.79 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LI, RUIXIANG is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +29.8% benefit to allowance rate for applications examined by LI, RUIXIANG. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 38.8% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 77.2% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 79.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 71.5% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.